Search

Your search keyword '"Etienne, Christophe Saint"' showing total 22 results
Start Over Author "Etienne, Christophe Saint" Language english
22 results on '"Etienne, Christophe Saint"'

5. Mitral transcatheter edge-to-edge repair vs. isolated mitral surgery for severe mitral regurgitation: a French nationwide study.

Author

Deharo, Pierre, Obadia, Jean Francois, Guerin, Patrice, Cuisset, Thomas, Avierinos, Jean Francois, Habib, Gilbert, Torras, Olivier, Bisson, Arnaud, Vigny, Pascal, Etienne, Christophe Saint, Semaan, Carl, Guglieri, Mickael, Dumonteil, Nicolas, Collart, Frederic, Gilard, Martine, Modine, Thomas, Donal, Erwan, Iung, Bernard, and Fauchier, Laurent

Subjects
MITRAL valve insufficiency, MITRAL valve surgery, PERCUTANEOUS balloon valvuloplasty, PROPENSITY score matching, ATRIAL fibrillation, PULMONARY edema, CARDIOVASCULAR disease related mortality
Abstract

Background and Aims Mitral valve surgery and, more recently, mitral transcatheter edge-to-edge repair (TEER) are the two treatments of severe mitral regurgitation in eligible patients. Clinical comparison of both therapies remains limited by the number of patients analysed. The objective of this study was to analyse the outcomes of mitral TEER vs. isolated mitral valve surgery at a nationwide level in France. Methods Based on the French administrative hospital discharge database, the study collected information for all consecutive patients treated for mitral regurgitation with isolated TEER or isolated mitral valve surgery between 2012 and 2022. Propensity score matching was used for the analysis of outcomes. Results A total of 57 030 patients were found in the database. After matching on baseline characteristics, 2160 patients were analysed in each arm. At 3-year follow-up, TEER was associated with significantly lower incidence of cardiovascular death (hazard ratio 0.685, 95% confidence interval 0.563–0.832; P =.0001), pacemaker implantation, and stroke. Non-cardiovascular death (hazard ratio 1.562, 95% confidence interval 1.238–1.971; P =.0002), recurrent pulmonary oedema, and cardiac arrest were more frequent after TEER. No significant differences between the two groups were observed regarding all-cause death (hazard ratio 0.967, 95% confidence interval 0.835–1.118; P =.65), endocarditis, major bleeding, atrial fibrillation, and myocardial infarction. Conclusions Our results suggest that TEER for severe mitral regurgitation was associated with lower cardiovascular mortality than mitral surgery at long-term follow-up. Pacemaker implantation and stroke were less frequently observed after TEER. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Acute Dental Periapical Abscess and New-Onset Atrial Fibrillation:A Nationwide, Population-Based Cohort Study

Author

Clementy, Nicolas, Bisson, Arnaud, Bodin, Alexandre, Herbert, Julien, Lacour, Thibaud, Etienne, Christophe Saint, Pierre, Bertrand, Deharo, Pierre, Babuty, Dominique, Fauchier, Laurent, Hassan, Amaar Obaid, Lip, Gregory, Harris, Rebecca, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of Liverpool, and Aalborg University [Denmark] (AAU)

Subjects
medicine.medical_specialty, Acute dental infection, Oral health, Epidemiology, 030204 cardiovascular system & hematology, Article, New onset, [SHS]Humanities and Social Sciences, 03 medical and health sciences, Population based cohort, 0302 clinical medicine, cardiovascular disease, Internal medicine, acute dental infection, Medicine, In patient, atrial fibrillation, Periapical abscess, business.industry, Area under the curve, Atrial fibrillation, Retrospective cohort study, 030206 dentistry, General Medicine, medicine.disease, Cardiovascular disease, New onset atrial fibrillation, Increased risk, oral health, Periapical Abscess, Cardiology and Cardiovascular Medicine, business, periapical abscess
Abstract

There are limited data on the relationship of acute dental infections with hospitalisation and new-onset atrial fibrillation (AF). This study aimed to assess the relationship between acute periapical abscess and incident AF. This was a retrospective cohort study from a French national database of patients hospitalized in 2013 (3.4 million patients) with at least five years of follow up. In total, 3,056,291 adults (55.1% female) required hospital admission in French hospitals in 2013 while not having a history of AF. Of 4693 patients classified as having dental periapical abscess, 435 (9.27%) developed AF, compared to 326,241 (10.69%) without dental periapical abscess that developed AF over a mean follow-up of 4.8 ± 1.7 years. Multivariable analysis indicated that dental periapical abscess acted as an independent predictor for new onset AF (p &lt, 0.01). The CHA2DS2VASc score in patients with acute dental periapical abscess had moderate predictive value for development of AF, with Area Under the Curve (AUC) 0.73 (95% CI, 0.71–0.76). An increased risk of new onset AF was identified for individuals hospitalized with dental periapical abscess. Careful follow up of patients with severe, acute dental periapical infections is needed for incident AF, as well as investigations of possible mechanisms linking these conditions.

Published
2021

8. To the Editor—Fear does not avoid the danger!

Author

Sambola, Antonia, Rello, Pau, Soriano, Toni, Bhatt, Deepak, Pasupuleti, Vinay, Cannon, Christopher, Gibson, C. Michael, Dewilde, Willem J.M., Lip, Gregory Y.H., Peterson, Eric, Airaksinen, K.E. Juhani, Kiviniemi, Tuomas, Fauchier, Laurent, Räber, Lorenz, Ruiz-Nodar, Juan, Banach, Maciej, Bueno, Héctor, Hernandez, Adrian, Deharo, Pierre, Bisson, Arnaud, Herbert, Julien, Lacour, Thibaud, Etienne, Christophe Saint, Porto, Alizée, Theron, Alexis, Collart, Frederic, Bourguignon, Thierry, Cuisset, Thomas, von Tokarski, Florent, Lemaignen, Adrien, Portais, Antoine, Hennekinne, Fanny, Sautenet, Bénédicte, Halimi, Jean-Michel, Legras, Annick, Patat, Frédéric, Mirguet, Christian, Bernard, Anne, Bernard, Louis, Clementy, Nicolas, Harvard Medical School [Boston] (HMS), Baim Institute for Clinical Research Boston MA, Beth Israel Deaconess Medical Center [Boston] (BIDMC), University of Liverpool, Liverpool Heart & Chest Hospital, Aalborg University [Denmark] (AAU), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), Medical University of Łódź (MUL), University of Zielona Góra, Hospital Universitario 12 de Octubre [Madrid], Centro Nacional de Investigaciones Cardiovasculares Carlos III [Madrid, Spain] (CNIC), Instituto de Salud Carlos III [Madrid] (ISC), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital de la Timone [CHU - APHM] (TIMONE), CHRU Brest - Service de Nephrologie (CHU - BREST - Nephrologie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Médecine Interne et Maladies Infectieuses [Tours], MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Hôpital Bretonneau, Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de réanimation cardio-vasculaire et thoracique, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Hôpital Pontchaillou, Centre de référence en infections ostéo-articulaires du grand-ouest [Rennes] (CRIOGO), and CHU Pontchaillou [Rennes]

Subjects
business.industry, Physiology (medical), Medicine, Fear, Medical emergency, Cardiology and Cardiovascular Medicine, business, medicine.disease, ComputingMilieux_MISCELLANEOUS, Defibrillators, Implantable, [SHS]Humanities and Social Sciences
Abstract

International audience

Published
2021

9. Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis

Author

Lantelme, Pierre, Lacour, Thibaud, Bisson, Arnaud, Herbert, Julien, Ivanes, Fabrice, Bourguignon, Thierry, Quilliet, Laurent, Angoulvant, Denis, Harbaoui, Brahim, Babuty, Dominique, Etienne, Christophe Saint, Deharo, Pierre, Bernard, Anne, Fauchier, Laurent, Collart, Frederic, Cuisset, Thomas, Sambola, Antonia, Rello, Pau, Soriano, Toni, Bhatt, Deepak, Pasupuleti, Vinay, Cannon, Christopher, Gibson, C. Michael, Dewilde, Willem J.M., Lip, Gregory Y.H., Peterson, Eric, Airaksinen, K.E. Juhani, Kiviniemi, Tuomas, Räber, Lorenz, Ruiz-Nodar, Juan, Banach, Maciej, Bueno, Héctor, Hernandez, Adrian, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), EA4245 - Transplantation, Immunologie, Inflammation [Tours] (T2i), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Harvard Medical School [Boston] (HMS), Baim Institute for Clinical Research Boston MA, Beth Israel Deaconess Medical Center [Boston] (BIDMC), University of Liverpool, Liverpool Heart & Chest Hospital, Aalborg University [Denmark] (AAU), Medical University of Łódź (MUL), University of Zielona Góra, Hospital Universitario 12 de Octubre [Madrid], Centro Nacional de Investigaciones Cardiovasculares Carlos III [Madrid, Spain] (CNIC), and Instituto de Salud Carlos III [Madrid] (ISC)

Subjects
medicine.medical_specialty, medicine.medical_treatment, Heart death, 030204 cardiovascular system & hematology, Prosthesis Design, Article, law.invention, [SHS]Humanities and Social Sciences, 03 medical and health sciences, 0302 clinical medicine, Percutaneous Coronary Intervention, Randomized controlled trial, law, Risk Factors, Internal medicine, Antithrombotic, Atrial Fibrillation, medicine, Stent, Humans, Myocardial infarction, cardiovascular diseases, 610 Medicine & health, ComputingMilieux_MISCELLANEOUS, Antithrombotic therapy, business.industry, Bleeding, Atrial fibrillation, Drug-Eluting Stents, Hematology, medicine.disease, Meta-analysis, Clinical effectiveness, Treatment Outcome, 030220 oncology & carcinogenesis, Relative risk, Conventional PCI, Cardiology, Systematic review, Stents, Heart infarction, business, Mace
Abstract

Objective: A systematic review and meta-analysis was performed to evaluate the safety and efficacy of drug-eluting stents (DES) vs bare-metal stents (BMS) in atrial fibrillation (AF) patients. Methods: We systematically searched 5 engines until May 2019 for cohort studies and randomized controlled trials (RCTs). Primary outcomes were major bleeding and major adverse cardiac events (MACE) including cardiac death, myocardial infarction, target vessel revascularization (TVR) or stent thrombosis. Effects of inverse variance random meta-analyses were described with relative risks (RR) and their 95% confidence intervals (CI). We also stratified analyses by type (triple [TAT] vs dual [DAT]) and duration (short-vs long-term) of antithrombotic therapy. Results: Ten studies (3 RCTs; 7 cohorts) including 10,353 patients (DES: 59.6%) were identified. DES did not show higher risk of major bleeding than BMS (5.6% vs 6.9%, RR 1.07; 95%CI, 0.89–1.28, p = 0.47; I2 = 0%) or MACE (12% vs 13.6%; RR 0.96; 95%CI 0.81–1.13, p = 0.60; I2 = 44%). Although, DES almost decreased TVR risk (6.4% vs 8.4%, RR 0.78; 95%CI, 0.61–1.01, p = 0.06; I2 = 15%). Stratified analyses by type and duration of antithrombotic therapy showed no differences in major bleeding or MACE between both types of stents. In DES, long-term TAT showed higher major bleeding risk than long-term DAT (7.7% vs 4.7%, RR 1.48, 95%CI 1.08–2.03, p = 0.01; I2 = 12%). For both types of stents, MACE risk was similar between TAT and DAT. Conclusions: In patients with AF undergoing PCI, DES had similar rate of major bleeding and MACE than BMS. DAT seems to be a safer antithrombotic therapy compared with TAT.

Published
2020

10. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study

Author

Cayla, Guillaume, Cuisset, Thomas, Silvain, Johanne, Henry, Patrick, Leclercq, Florence, Carrié, Didier, Etienne, Christophe Saint, Belle, Loic, Rangé, Grégoire, Pouillot, Christophe, Varenne, Olivier, Van Belle, Eric, Boueri, Ziad, Motreff, Pascal, Elhadad, Simon, Delarche, Nicolas, El Mahmoud, Rami, Vicaut, Eric, Collet, Jean-Philippe, and Montalescot, Gilles

Published
2014
Full Text
View/download PDF

17. Incomplete recovery of mechanical and endocrine left atrial functions one month after electrical cardioversion for persistent atrial fibrillation: a pilot study.

Author

Bernard-Brunet, Anne, Etienne, Christophe Saint, Piver, Eric, Zannad, Noura, Pagés, Jean-Christophe, Fauchier, Laurent, and Babuty, Dominique

Subjects
*ELECTRIC countershock, *ATRIAL fibrillation treatment, *ATRIAL fibrillation, *ECHOCARDIOGRAPHY, *ATRIAL natriuretic peptides
Abstract

Background Restoration of the mechanical and endocrine functions of the left atrium remains controversial after electrical cardioversion treatment for persistent atrial fibrillation. The objective of the prospective study was to describe the recovery of the endocrine and mechanical functions of the left atrium. Methods Evaluation of left atrium recovery after electrical cardioversion by the new speckle-tracking echocardiography technique and proANP measurement. Results Twenty patients suffering from persistent atrial fibrillation with no alteration of left ventricular ejection fraction were prospectively evaluated at baseline and then one month later by echocardiography, measuring left atrial volume and left atrial deformation (MPALS), as well as the proANP and BNP concentrations. One month after cardioversion 10 patients remained in sinus rhythm and 10 showed recurrent atrial fibrillation. No significant differences between the two groups in terms of clinical, echocardiographic and endocrine parameters were observed at baseline evaluation. We observed a significant reduction of left atrial volume only in the sinus group, whereas restoration of the left atrial deformation was only partial (18%) in that group. By contrast, we registered no significant changes in ANP concentration at one month in either the sinus or the atrial fibrillation groups. Conclusion These results suggest that restoration of left atrium mechanical function is only partial one month after treatment of persistent atrial fibrillation by electrical cardioversion, whereas a significant reduction of left atrial volume was noted, explaining the remaining high level of ANP in the sinus group. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

20. Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement.

Author

Deharo, Pierre, Bisson, Arnaud, Herbert, Julien, Lacour, Thibaud, Etienne, Christophe Saint, Porto, Alizée, Theron, Alexis, Collart, Frederic, Bourguignon, Thierry, Cuisset, Thomas, and Fauchier, Laurent

Subjects
*PROSTHETICS, *RESEARCH, *RESEARCH methodology, *AORTIC stenosis, *RETROSPECTIVE studies, *EVALUATION research, *MEDICAL cooperation, *TREATMENT effectiveness, *COMPARATIVE studies, *PROSTHETIC heart valves, *REOPERATION, *PROBABILITY theory, *LONGITUDINAL method, AORTIC valve surgery
Abstract

Background: Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) and redo surgical aortic valve replacement (SAVR) represent the 2 treatments for aortic bioprosthesis failure. Clinical comparison of both therapies remains limited by the number of patients analyzed.Objectives: The purpose of this study was to analyze the outcomes of VIV TAVR versus redo SAVR at a nationwide level in France.Methods: Based on the French administrative hospital-discharge database, the study collected information for patients treated for aortic bioprosthesis failure with isolated VIV TAVR or redo SAVR between 2010 and 2019. Propensity score matching was used for the analysis of outcomes.Results: A total of 4,327 patients were found in the database. After matching on baseline characteristics, 717 patients were analyzed in each arm. At 30 days, VIV TAVR was associated with lower rates of the composite of all-cause mortality, all-cause stroke, myocardial infarction, and major or life-threatening bleeding (odds ratio: 0.62; 95% confidence interval: 0.44 to 0.88; p = 0.03). During follow-up (median 516 days), the combined endpoint of cardiovascular death, all-cause stroke, myocardial infarction, or rehospitalization for heart failure was not different between the 2 groups (odds ratio: 1.18; 95% confidence interval: 0.99 to 1.41; p = 0.26). Rehospitalization for heart failure and pacemaker implantation were more frequently reported in the VIV TAVR group. A time-dependent interaction between all-cause and cardiovascular mortality following VIV TAVR was reported (p-interaction <0.05).Conclusions: VIV TAVR was observed to be associated with better short-term outcomes than redo SAVR. Major cardiovascular outcomes were not different between the 2 treatments during long-term follow-up. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results